CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Phase II Clinical Study of CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (inclusive)

This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Study Overview

• Status: Recruiting
• Conditions: Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
• Intervention / Treatment: Biological: CAR-T-19 cell injection

Detailed Description

This is a multiple-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collection of autologous lymphocytes, patients will then proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m^2 and fludarabine 30mg/m^2 for 3 consecutive days followed by the infusion of CD19 CAR T-cells at a target dose of 2.5 x10^6 cells/kg（range 0.8-2.5×10^6 cells/kg）.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Xiaofan Zhu; Phone Number: 022-23909137; Email: xfzhu@ihcams.ac.cn

Study Locations

• China
  • Tianjin, China
    • Recruiting
    • Hematology Hospital of the chinese Academy of Medical Sciences
    • Contact: Xiaofan Zhu; Phone Number: 022-23909137; Email: xfzhu@ihcams.ac.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntary participation in clinical trial, The Participants or his legal guardian is fully understands this clinical trial and signs the Informed Consent Form (ICF); Willing to follow and be able to complete all trial procedures.
2. Age≤25 years old at the time of screening, regardless of gender.
3. Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions： Relapsed B-ALL：1）Relapse within 12 months of the first remission；2）Recurrence occurring again more than 12 months after the first remission,, relapsed or not responded after first-line/multi-line salvage chemotherapy；3) Experienced two or more bone marrow recurrences; 4） recurrence after autologous or allogeneic hematopoietic stem cell transplantation； Refractory B-ALL：1）failed to achieve complete remission after 2 cycles of standard induction chemotherapy.
4. Ph+ALL patients are eligible：1）Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments；If Ph+ALL patients with t315i mutation are resistant to first- and second-generation TKIs, in the absence of effective TKI therapy, patients are not required to receive at least two TKIs；2）cannot tolerate TKI treatment；3）Presence of contraindications to TKI therapy.
5. Bone marrow (BM) or peripheral blood (PB) tumor cells were measured to express CD19 at screening.
6. Bone marrow blasts ≥ 5% at screening.
7. Adequate organ function and must meet the following criteria： Alanine aminotransferase (ALT) ≤ 5 ×Upper limit of normal value(ULN)；Total serum bilirubin ≤ 2.0 ×ULN(（for Gilbert syndrome, total bilirubin≤3.0×ULN)；in non-oxygen state, No > grade 1 dyspnea, Blood oxygen saturation > 95%；left ventricular ejection fraction(LVEF) ≥ 50%；Serum creatinine≤1.5 × ULN；
8. Karnofsky（age≥16 years）performance status≥70 or Lansky（age<16 years）performance status≥50.
9. Life expectancy ≥ 12 weeks.
10. Adequate venous access (for apheresis) and no other contraindications to apheresis.
11. Negative blood/urine pregnancy test in women of childbearing potential before screening and within 3 days prior to cell infusion, and any male and female patients of childbearing potential must agree to use an effective method of contraception throughout the study and for at least 2 years after CAR-T-19 infusion. In the judgment of the investigator, a patient of childbearing potential means that he/she is biologically capable of having children and having a normal sexual life.
12. For Participants who have previously undergone allogeneic hematopoietic stem cell transplantation, CAR-T-19 cell preparation is performed using their previous donor peripheral blood， and the donor needs to meet the following conditions：1）Have donated bone marrow/hematopoietic stem cells as a transplant donor for the patient；2）Age ≥8 years at screening；3）Voluntary participation in clinical studies; the donor (and legal guardian, if applicable) am fully aware of and informed about this trial and have signed an informed consent form (ICF); Willing to follow and be able to complete all trial procedures；4）Have adequate venous access (for apheresis or venous blood collection) and no other contraindications to apheresis; 5) The etiological test results do not correspond to any of the exclusion criteria outlined in item 12. 6) Women of childbearing age have negative blood and urine pregnancy tests.7) Systemic glucocorticoid therapy is prohibited within one week prior to apheresis, with the exception of physiologically replacement doses of glucocorticoids (0.5 mg/kg/day of prednisone or equivalent doses of other corticosteroids).8) There are no cases of uncontrolled fungal, bacterial, viral, or other infections requiring intravenous treatment.

Exclusion Criteria:

1. Isolated extra-medullary disease relapse .
2. Participants with genetic syndromes, Patients with Down Syndrome will not be excluded.
3. Participants with Burkitt's lymphoma/leukemia.
4. Participants with active central nervous system disease.
5. Active central nervous system leukemia at screening(Defined as CNS-3 and CNS-2 grades with neurological symptoms as defined by NCCN guidelines and judged by the investigator to be active central leukemia).
6. Participants with a history of other malignant tumors or other malignant tumors at the same time (excluding fully treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, thyroid cancer, ductal carcinoma in situ after radical resection).
7. have or suspected to have fungal, bacterial, viral or other infections that are uncontrollable or require intravenous treatment.
8. Participants who have received HSCT within 3 months before screening or Presence of grade 2 to 4 active graft-versus-host disease (GVHD), and those who have received systemic drug therapy for GVHD within 4 weeks before infusion.
9. Received the following anti-tumor therapy before apheresis：1）Received any chemotherapy, targeted therapy, etc. within 4 weeks or at least 5 half-lives (whichever is shorter)；2）Radiotherapy within 14 days；3）Intrathecal treatment within 7 days；4) Received a donor lymphocyte transfusion (DLI) within 4 weeks; 5)Received Blinatumomab within 14 days.
10. Participants who have been treated with systemic glucocorticoids within 1 week before apheresis, physiological replacement doses of steroids are allowed.
11. Long-acting G-CSF is prohibited within 21 days and short-acting G-CSF is prohibited within 7 days before apheresis.
12. Any of the following applies:1）Hepatitis B surface antigen (HBsAg) positive or HBV-DNA quantity is higher than the upper limit of normal value；2）Hepatitis C virus antibody (HCV Ab) is positive and HCV RNA quantification is higher than the upper limit of normal values;3）Positive for human immunodeficiency virus antibody (HIV-Ab);4）EB virus DNA quantification is higher than the upper limit of normal values;5）Cytomegalovirus DNA quantification is higher than the upper limit of normal values.
13. Those who have received CAR-T therapy with any target.
14. Allergy to albumin and aminoglycoside antibiotics.
15. Received live vaccine within 6 weeks before screening.
16. Participants after organ transplantation (except hematopoietic stem cell transplantation).
17. participated in other interventional clinical studies (received active trial drug treatment) within 3 months before screening, or intend to participate in another clinical trial or receive another anti-tumor therapy.
18. Other investigators deem it inappropriate to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CAR-T-19 cells; CAR-T-19 cells injection: 2.5 x10^6 cells/kg（range 0.8-2.5×10^6 cells/kg）	Biological: CAR-T-19 cell injection; The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate(ORR)	ORR included complete response (CR) and CR with incomplete blood count recovery (CRi) as determined by an Independent Review Committee（IRC） assessment.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	ORR at 3 months after CAR-T-19 infusion as assessed by investigator.	3 months
ORR	ORR at 28 days after CAR-T-19 infusion as assessed by IRC and investigator.	28 days
Minimal residual disease（MRD）	MRD-negative ORR as assessed by Independent Review Committee (IRC) and investigator.	3 months
Best overall response (BOR)	BOR as assessed by Independent Review Committee (IRC) and investigator.	2 years
Duration of response (DOR)	DOR as assessed by Independent Review Committee (IRC) and investigator.	2 years
Overall survival (OS)	Overall survival means the time from infusion of CAR-T-19 cells to death of participants from any cause.	2 yeas
Pharmacodynamics	The degree of clearance of CD19-positive B cells at different blood collection time points after cell infusion.	2 years
Event Free Survival（EFS）	EFS as assessed by Independent Review Committee (IRC) and investigator.	2 years
Recurrence Free Survival（RFS）	RFS as assessed by Independent Review Committee (IRC) and investigator.	2 years
AE safety	Number of participants with Adverse event (AE).	2 years
SAE safety	Number of participants with Serious adverse event (SAE)	2 years
ADA safety	Number of participants with Anti-drug antibody(ADA).	2 years
RCL safety	Number of participants with Replication Competent Lentivirus (RCL).	15 years
Pharmacokinetics (PK) Parameter-Cmax	Cmax	2 years
Pharmacokinetics (PK) Parameter-Tmax	Tmax	2 years
Pharmacokinetics (PK) Parameter-AUC0-t	AUC0-t	2 years
Pharmacokinetics (PK) Parameter- AUC0-28d	AUC0-28d	2 years
Pharmacokinetics (PK) Parameter- t1/2	t1/2	2 years
Serum cytokines-Interleukin 6	The concentration levels of Interleukin 6（ IL-6）at each time point .	28 days
Serum cytokines-Interleukin 10	The concentration levels of Interleukin 10（ IL-10）at each time point .	28 days
Serum cytokines-TNF-α	The concentration levels of tumor necrosis factor -α（ TNF-α） at each time point .	28 days
Serum cytokines-INF-γ	The concentration levels of Interferon -γ（INF-γ） at each time point .	28 days

Collaborators and Investigators

• Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
• Investigators: Principal Investigator: Xiaofan Zhu, Hematology Hospital of the chinese Academy of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): January 3, 2024
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: December 1, 2023
• First Submitted That Met QC Criteria: December 19, 2023
• First Posted (Actual): December 22, 2023

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 9, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Leukemia; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Other Study ID Numbers: CT19-ALL-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No